Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 19, 2020
Role of Culture, Values, and Politics in the Implementation of Health Technology Assessment in India: A CommentaryShilpi Swami, Tushar Srivastava
Langmuir : the ACS Journal of Surfaces and Colloids|November 15, 2021
Droplet Impact and Spreading on Inclined SurfacesTushar Srivastava, Santosh Kumar Jena, Sasidhar Kondaraju
Pharmacoeconomics|May 19, 2021
Estimation of Transition Probabilities for State-Transition Models: A Review of NICE AppraisalsTushar Srivastava, Nicholas R Latimer, Paul Tappenden
Advances in Therapy|June 25, 2025
Integration of Generative AI with Human Expertise in HEOR: A Hybrid Intelligence FrameworkTushar Srivastava, Hanan Irfan, Vladimir Babiy, et al.
Clinical Drug Investigation|November 3, 2020
Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in AustraliaMasnoon Saiyed, Joshua Byrnes, Tushar Srivastava, et al.
Journal of Forensic Sciences|December 2, 2017
A Three-Locus, PCR-based Method for Forensic Identification of Plant MaterialTushar Srivastava, Michael Wu, Julia Kakhnovich, et al.
Clinicoeconomics and Outcomes Research : CEOR|June 20, 2023
A Systematic Review and Statistical Analysis of Factors Influencing the Cost-Effectiveness of Transcatheter Aortic Valve Implantation for Symptomatic Severe Aortic StenosisLaura Heathcote, Tushar Srivastava, Archita Sarmah, et al.
Leukemia & Lymphoma|May 23, 2025
Toxicity, progression-free survival, and quality of life of patients treated with zanubrutinib versus ibrutinib: a Q-TWiST analysis from the ALPINE study in relapsed or refractory chronic lymphocytic leukemiaVincent Lévy, Tushar Srivastava, Raju Gautam, et al.
Pharmacoeconomics|January 18, 2023
Living Health Technology Assessment: Issues, Challenges and OpportunitiesPraveen Thokala, Tushar Srivastava, Robert Smith, et al.
Leukemia & Lymphoma|September 1, 2025
Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphomaBijal Shah, Swetha Challagulla, Sheng Xu, et al.
Pageof 2